Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Propsci Perspectives: LabCentral/BioLabs

Related Content

Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe

Sun Pharma Launches ILUMYA® in India

FDA Approves mAbxience and Amneal’s Denosumab Biosimilars

Biocon and Regeneron Enter Global Settlement on Aflibercept Biosimilar

CareFirst’s Class Action STELARA® Antitrust Case Against J&J Will Proceed: Court Grants-in-Part and Denies-in-Part Class Certification and Denies the Parties’ Motions for Summary Judgment

Regeneron Seeks to Bifurcate or Stay Amgen’s Antitrust Claims in Aflibercept Patent Litigation

CMS Releases MFN Drug Pricing Models for Medicare Parts B and D and Medicaid Amid Trump Administration’s Push for Direct-to-Consumer Strategy

Vertex Presents New CASGEVY® Data in Patients 5-11 Years and Announces Plan for Global Regulatory Submissions

Goodwin Advises Noetik in Licensing AI Foundation Models in Anchor Partnership with GSK

Goodwin Represents Nimbus Therapeutics in Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment for Up to $1.3 Billion

Goodwin Guides Parabilis Medicines in Oversubscribed $305 Million Financing

Goodwin Advises Corsera Health on $80 Million Series A Financing

Goodwin Releases 2025-26 Update to Annual Biosimilars Guide

Goodwin Advises Dark Blue Therapeutics on $840 Million Acquisition

Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

Goodwin Expands Life Sciences Team with the Arrival of European Patent Attorney Colm Murphy in London

Life Sciences